MCRB 20.59 ▼ -2.14% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Seres Therapeutics Inc.

    NASDAQ: MCRB · Real-Time Price · USD
    20.59
    -0.45 (-2.14%)
    At close: Oct 03, 2025, 3:59 PM
    20.59
    0.00%
    After-hours: Oct 03, 2025, 06:36 PM EDT
    -2.14%
    Bid 15.72
    Market Cap 180.26M
    Revenue (ttm) 5.96M
    Net Income (ttm) 85.97M
    EPS (ttm) -6.79
    PE Ratio (ttm) -3.03
    Forward PE -2.04
    Analyst Hold
    Dividends n/a
    Ask 24.75
    Volume 261,935
    Avg. Volume (20D) 176,646
    Open 21.35
    Previous Close 21.04
    Day's Range 19.14 - 21.97
    52-Week Range 6.53 - 24.66
    Beta 0.20
    Ex-Dividend Date n/a

    About MCRB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol MCRB
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for MCRB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Seres Therapeutics Inc. is scheduled to release its earnings on Nov 12, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 months ago
    -10.54%
    Seres Therapeutics shares are trading lower follow... Unlock content with Pro Subscription
    5 months ago
    -16.04%
    Seres Therapeutics shares are trading lower after Chardan Capital downgraded the stock from Buy to Neutral.
    news image

    1 week ago · reuters.com

    More companies adopt co-CEO structure

    Enterprise software maker Oracle on Monday named insiders Clay Magouyrk and Mike Sicilia as co-CEOs, replacing Safra Catz, who was named vice chair of the board after 11 years at the helm.

    news image

    3 weeks ago · zacks.com

    All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy

    Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    1 month ago · zacks.com

    Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross

    After reaching an important support level, Seres Therapeutics, Inc. (MCRB) could be a good stock pick from a technical perspective. MCRB recently experienced a "golden cross" event, which saw its 50-d...

    news image

    2 months ago · seekingalpha.com

    Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript

    Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Carlo Tanzi - Corporate Participant Investor Relations - Corporate Participant D...

    news image

    2 months ago · fool.com

    Seres (MCRB) Q2 Loss Narrows 34%

    Seres (MCRB) Q2 Loss Narrows 34%

    news image

    2 months ago · seekingalpha.com

    Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

    Seres Therapeutics's VOWST divestiture injected cash, retired debt, and refocused the company as a clinical‑stage microbiome specialist. Their current lead candidate is SER‑155, which seems to reduce ...

    Add to Watchlist